



Alberto Aguilera,7.
28015 Madrid. Spain.
Phone +34 912.670.900
Fax +34 912.670.901
info@tcdpharma.com
www.tcdpharma.com

TCD Pharma Announces €1.5M Equity Investment by ADE Capital Sodical SCR

The funds will enable the Company to continue the development of TCD-717, its leading product currently in a Phase I clinical trial for the treatment of cancer, as well as expanding its pipeline.

Valladolid, January 10, 2012 – TCD Pharma, a privately held clinical stage biotechnology company focused on developing and commercializing innovative therapies that address unmet medical needs in Oncology, today announced that ADE Capital Sodical SCR (“Sodical”), has joined TCD's current investors Cross Road Biotech, Seguranza F.C.R., and Real de Vellón SCR (the two latter funds are managed by Clave Mayor SGCR) by participating to the amount of €1.5 million in the Company's Series B Extension financing round.

"We are very pleased to add Sodical as an investor in TCD," said Ran Vigdor, TCD's Chief Executive Officer. "With the support of all our investors, we are committed to developing TCD-717, our lead product candidate, as well as expanding our pipeline as a base for a sustainable and attractive biotechnology company".

For more information please contact us at communication@tcdpharma.com

Visit us at www.tcdpharma.com or www.facebook.com/TCDPharma

About TCD Pharma

Chosen as one of Spain's top 5 biotech investment opportunities, TCD Pharma is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs.

Established in 2005 TCD Pharma is positioning itself as Spain's Partner of Choice for Oncology drug discovery and development opportunities.

TCD Pharma's leading product, TCD-717, is currently being evaluated in a Phase I clinical study as treatment for solid tumors. The study has been approved by the FDA and is currently being conducted in two leading medical centers in the U.S.

TCD Pharma's strong management team, its strategy of building its pipeline through in-licensing and its ability to leverage resources through outsourcing, allows TCD Pharma to be in the forefront of Oncology drug development while significantly lowering risks and costs.

About ADE Capital Sodical SCR, SA

Founded in 1982, Ade Capital Sodical SCR, SA. invests financial resources in companies that contribute to the development of Castilla y Leon, through a temporal and minority stake in their share capital.

ADE Capital Sodical SCR issues medium and long term loans to the participating companies, and also participating loans as another way to add value.

The funds managed by ADE Capital Sodical SCR has reached 59€ million, with the Agencia de Inversiones y Servicios de Castilla y León (32,50%), financial institutions (51,44%) and other entities (16,06%) as the current shareholders.



ADE Capital Sodical SCR has a portfolio of 39 companies, focused in the main important sectors in Castilla y Leon, including the Food Industry, automotive, metal, chemical, renewable energy and rural tourism industries and strategic sectors including the aeronautic and biotechnology industries.

Safe Harbor

Certain statements in this news release are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing, developments and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. are made only as of the date of this release, and TCD undertakes no obligation to update them to reflect subsequent events or circumstances.